Bristol Myers Squibb’s science-powered and patient-centric mission is accelerating, driven in part by transformational advancements in AI/ML.
Bristol Myers Squibb, a biopharmaceutical company, and Accenture has announced the official opening of a new AI-powered content hub, ‘Mosaic’, in Mumbai.
BMS is investing $130 million to advance a portfolio of AI initiatives and AI-enabled capabilities across marketing. The Mosaic content hub is a component of this investment.
Bristol Myers Squibb has a strong presence in India through its commercial operations for more than two decades, offering medicines in oncology, hematology and cardiology. The company also opened a facility in Hyderabad recently, home to more than 3,000 Business Insights and Technology, Global Drug Development, Global Product Development and Supply, Enabling Functions employees.
The end-to-end, generative AI-enabled content hub will accelerate BMS’s commercialisation through enhanced digital capabilities, which will help identify physician’s educational needs in real-time, enabling rapid creation of patient-centric content.
The Mosaic content hub was officially launched today in Mumbai by Adam Lenkowsky, Chief Commercialisation Officer of Bristol Myers Squibb, and Ndidi Oteh, global CEO of Accenture Song.
“The future of healthcare is about meeting clinicians and patients where they are and doing so in meaningful ways. This partnership reflects our BMS approach to end-to-end digital transformation,” said Lenkowsky. “The Mosaic content hub will ultimately improve patient experience by making it easier for our marketing teams to create and share timely, tailored communications with health care professionals.”
Bristol Myers Squibb’s science-powered and patient-centric mission is accelerating, driven in part by transformational advancements in AI/ML.
Bristol Myers Squibb and Accenture have built a partnership for more than 25 years. What began as traditional service delivery has evolved into an engine for digital transformation, with Accenture bringing talent and capabilities to support Bristol Myers Squibb’s priorities.
The partnership with Accenture to launch a content hub in Mumbai will bring together a large team of creatives and technologists.
“Accenture and Bristol Myers Squibb are leading the AI-forward reinvention of biopharma by applying innovative technologies to generate meaningful outcomes for patients. Mosaic is a powerful example of how Bristol Myers Squibb is driving industry transformation and setting a new standard for hyper-personalised experiences for healthcare professionals,” said Accenture Song’s CEO, Ndidi Oteh.
More Like This
Published on December 17, 2025
